Indication
JAK2 Gene Mutation
2 clinical trials
2 products
Clinical trial
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic DisordersStatus: Recruiting, Estimated PCD: 2025-11-30
Product
RuxolitinibClinical trial
Post-Transplant Use of Irradiated Haplo-Allogeneic CellsStatus: Terminated, Estimated PCD: 2022-06-30
Product
Irradiated Allogeneic Cells